Moderna Therapeutics, a biotechnology firm that is developing drugs that work on a genetic messaging system that is essentially to all living cells, has raised $500 million from a group of new and current investors.
The true cost of healthcare is often a mystery to consumers. If a new initiative by Amazon, Berkshire Hathaway and JPMorgan Chase can bring more transparency to the U.S. healthcare system, that could be bad news for insurers and pharmacy benefit managers.
AstraZeneca is sued by Array BioPharma over cancer drug royalties | Reuters
Flu Vaccines Won’t Improve Without a Massive Incentive for Big Pharma | WIRED
AstraZeneca expects to return to drug sales growth in 2018 as new medicines win market share and the group puts patent losses behind it, although the need to invest in launches will weigh on profit.
Vertex Picks 'Impressive' Cystic Fibrosis Drugs To Aim For A Multibillion-Dollar Market - Forbes
Eli Lilly CEO rebuffs Trump's attack on drug prices - CNBC
Biotech deal-making is the hottest in more than a decade with $27.5 billion of transactions agreed this month and bankers reporting an above-average number of discussions that could lead to fresh activity through 2018.
Trump touts faster generic drug approvals to bring down prices - The Washington Post http://ow.ly/1pFB30i8KUm
Sanofi CEO: $16 Billion Deal Binge Does Not Represent A Change In Strategy - Forbes
Danish drugmaker Novo Nordisk will continue to hunt for promising assets to refill its blood products business, after losing out to Sanofi in a $4.8 billion fight for Belgian biotech company Ablynx.
Why Sanofi Is Buying Belgian Biotech Company Ablynx for Nearly $5 Billion | Fortune
Paying a monster price is one way to secure a deal. Sanofi has applied this crude method twice in eight days. The French drugmaker’s reputation as a risk-averse acquirer needs revisiting.
Brexit could leave patients unable to access new drugs | The Guardian
French group beats interest from Novo Nordisk to make second major acquisition in a week